Geldanamycin (NSC 122750)

Name: Geldanamycin (NSC 122750)
Brand: Selleck Chemicals
SKU: S2713
Rating: 5 (25 reviews)

For research use only.

Catalog No.S2713

25 publications

Geldanamycin (NSC 122750) Chemical Structure

CAS No. 30562-34-6

Geldanamycin (NSC 122750) is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association. Geldanamycin attenuates virus infection-induced ALI (acute lung injury)/ARDS (acute respiratory distress syndrome) by reducing the host's inflammatory responses.

Selleck's Geldanamycin (NSC 122750) has been cited by 25 publications

Cell Chem Biol, 2021, S2451-9456(21)00221-X

PubMed: 34077750 ( click the link to review the publication )

J Virol, 2021, JVI0059421

PubMed: 34037421 ( click the link to review the publication )

Anal Chem, 2020, 92(1):1363-1371

PubMed: 31794197 ( click the link to review the publication )

Anal Chem, 2020, 10.1021/acs.analchem.0c02756

PubMed: 32933243 ( click the link to review the publication )

Cell Biol Toxicol, 2020,

PubMed: 31773452 ( click the link to review the publication )

Proteomics, 2020, e1900372

PubMed: 32578935 ( click the link to review the publication )

Virology, 2020, 553:70-80

PubMed: 33242760 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2131

PubMed: 31086186 ( click the link to review the publication )

Autophagy, 2019, 15(9):1558-1571

PubMed: 30821613 ( click the link to review the publication )

EBioMedicine, 2019, 47:170-183

PubMed: 31466918 ( click the link to review the publication )

J Biol Chem, 2019, 294(11):4247-4258

PubMed: 30670591 ( click the link to review the publication )

Food Chem Toxicol, 2019, 132:110645

PubMed: 31254591 ( click the link to review the publication )

Autophagy, 2018, 14(6):958-971

PubMed: 29561705 ( click the link to review the publication )

Mol Syst Biol, 2018, 14(7):e8071

PubMed: 29997244 ( click the link to review the publication )

Toxicol Sci, 2018,

PubMed: 30137596 ( click the link to review the publication )

Radiat Res, 2018, 189(5):519-528

PubMed: 29474156 ( click the link to review the publication )

Hum Mol Genet, 2017, 26(22):4465-4480

PubMed: 28973376 ( click the link to review the publication )

Arch Toxicol, 2016, 90(1):159-80

PubMed: 26705709 ( click the link to review the publication )

Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7

PubMed: ( click the link to review the publication )

J Antimicrob Chemother, 2015, 10.1093/jac/dku549

PubMed: 25558076 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(8):4727-33

PubMed: 26014950 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0138936

PubMed: 26414348 ( click the link to review the publication )

Cell Stress Chaperones, 2015, 20(2):309-19

PubMed: 25576151 ( click the link to review the publication )

J Mol Neurosci, 2015, 57(3):317-24

PubMed: 26208597 ( click the link to review the publication )
Oncotarget, 2014, 5(12):4269-82

PubMed: 24962213 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description

Targets

p185 ^[4] (SKBr3 cells)	HSP90 (N-terminal domain) ^[1] (Cell-free assay)	HSP90 ^[1] (Cell-free assay)
70 nM	0.78 μM(Kd)	1.2 μM(Kd)

In vitro

Geldanamycin binds in the ATP-binding site in the N-terminus domain of Hsp90s (residues 1-220). Geldanamycin inhibits the ATPase activity of Hsp90 in a dose-dependent manner. ^[1] Geldanamycin causes a dose-dependent G2 arrest and reversible inhibiton o f entry into the S phase in A2780 human ovarian cell line. This inhibition is accompanied by p53 increase and finally demonstrated to be p53 dependent. ^[2] Geldanamycin causes polyubiquitination and proteasomal degradation of the p185 receptor protein-tyrosin kinase and shows a IC50 with 70 nM. ^{[3, 4]} Geldanamycin is a typical anti-tumor reagent, shows a mean GI50 with 0.18 μM against the panel of 60 human tumor cell lines. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
A2780 cells	NXry[WVvWHKxbHnm[ZJifGmxbjDhd5NigQ>?			M{Ho[GNwdXCxdX7kJJdieyCndnHseYF1\WRiZn;yJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5ib4\hdolidiClYYLjbY5wdWFiY3XscEBtcW6nIFGyO\|gxNCCLQ{WwQVMvPCEQvF2=	MkjQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF3MUSxOFUoRjFzNUG0NVQ2RC:jPh?=
SW620 cell	M{e2NGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MoH2TY5pcWKrdH;yfUBkd26lZX70doF1cW:wIHHnZYlve3RiaIXtZY4h[2:ub4LlZ5RidCClYYLjbY5wdWFiU2e2NlAh[2WubDDsbY5meyxiSVO1NF03NjJibl2=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTZ3OEi3PUc,OTV4NUi4O\|k9N2F-
MCF-7 cell	M4HwVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MoT3TY5pcWKrdH;yfUBkd26lZX70doF1cW:wIHHnZYlve3RiaIXtZY4h[nKnYYP0JINidmOncjDNR2YuPyClZXzsJIxqdmW\|LDDJR\|UxRTZwNTDuUS=>	M3LmTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NkW4PFc6Lz5zNU[1PFg4QTxxYU6=
K562 cell	NEfjeYRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			M{\5W2lvcGmkaYTvdpkh[2:wY3XueJJifGmxbjDh[4FqdnO2IHj1cYFvKGyndXvlcYliKEt3NkKgZ4VtdCCuaX7ld{whUUN3ME2yNk4yKG6P	M4D1flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NkW4PFc6Lz5zNU[1PFg4QTxxYU6=
HT-29 cell	MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M3r0XmlvcGmkaYTvdpkh[2:wY3XueJJifGmxbjDh[4FqdnO2IHj1cYFvKGOxbH;y[YN1[WxiY3HyZ4lvd22jIFjUMVI6KGOnbHygcIlv\XNuIFnDOVA:OjRwNTDuUS=>	Ml\3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV4NUi4O\|koRjF3NkW4PFc6RC:jPh?=
SK-BR-3	NWPCO25FTnWwY4Tpc44h[XO\|YYm=	M1W4WlUxKG2pL3vn		M2O2SmlvcGmkaYTpc44hd2Zib37jc4dmdmVicILv[JVkfCCyMUi1JIVz[kJvMjDmdo9uKGi3bXHuJIJz\WG\|dDDjZY5k\XJiY3XscJMpW0tvQmKtN{Bk\WyuczmgZZQhPTBibXevb4ch\G:\|ZTygTWM2OD1yLkC3{txO	M3nrSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzd3NkK5NVEoRjd3NkK5NVE9N2F-
SK-BR-3	NFjXVnBHfW6ldHnvckBie3OjeR?=			NWG1XWtqUW5idnn0do8hcW6qaXLpeIlwdiCxZjDwNVg2KGW{YlKtNkBwdmOxcILveIVqdiCrbjDoeY1idiCkcnXhd5Qh[2GwY3XyJHNMNUKULUOgZ4VtdHNuIFnDOVA:OC5yN988US=>	M{[xelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzd3NkK5NVIoRjd3NkK5NVI9N2F-
MCF-7	M{PVSWZ2dmO2aX;uJIF{e2G7			M4O1VWlvcGmkaYTpc44hd2Zic4TlZYR6NXO2YYTlJIV5eHKnc4Ppc44hd2ZiSFXSNkBqdiCPQ1[tO{BjemWjc4SgZ4Fv[2W{IHPlcIx{NCCLQ{WwQVAvODYQvF2=	NGLUboQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMEO0NFYxPSd-MUCzOFA3ODV:L3G+
MCF-7	MmTuSpVv[3Srb36gZZN{[Xl?			NImzNYNKdmirYnn0bY9vKG:oIIP0[YFlgS2\|dHH0[UBmgHC{ZYPzbY9vKG:oIFXSJIlvKE2FRj23JIJz\WG\|dDDjZY5k\XJiY3XscJMtKEmFNUC9NE4xPs7:TR?=	NH;hOWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMEO0NFYxPSd-MUCzOFA3ODV:L3G+
MCF-7	M{nQNGZ2dmO2aX;uJIF{e2G7			NV7BS5V4UW6qaXLpeIlwdiCxZjDzeIVi\Hlvc4TheIUh\XiycnXzd4lwdiCxZjDSZYYuOSCrbjDNR2YuPyCkcnXhd5Qh[2GwY3XyJINmdGy\|LDDJR\|UxRTBwMt88US=>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODN2ME[wOUc,OTB\|NEC2NFU9N2F-
SKBR-3	NG\BVY9HfW6ldHnvckBie3OjeR?=			NGXJcYhG\m[nY4TpeoUh[2:wY3XueJJifGmxbjDmc5IhUGW{LUKg[IVoemGmYYTpc44hcW5iU1vCVk0{KGOnbHzzMEBEd26lZX70doF1cW:wPUZOwG0>	NWf0S2Y6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW3NVM1OTBpPkG1O\|E{PDFyPD;hQi=>
HEK293	NGjURZdHfW6ldHnvckBie3OjeR?=			MkDVTY5pcWKrdHnvckBw\iCKU2C5NEBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJIF{e2W\|c3XkJIF{KGWoZnXjeEBwdiCDa4SxPpAzPyCrboTldoFkfGmxbjDjc41xdGW6ZYOgZpkhTVmIUDDhcoQwd3JiWV\QJHZmdnW\|IH\yZYdu\W62IHLhd4VlKHKncH;yeIVzKGenbnWgZZN{[Xl?	Mkj6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ4OECxOVkoRjF4NkiwNVU6RC:jPh?=
LS174T	M{\1PGN6fG:2b4jpZ4l1gSCjc4PhfS=>			NVzZV3Q5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVFNzN{TUJINmdGy\|IHL5JG1VWyCjc4PhfUwhUUN3ME2wMlQ2\|ryP	NIi5Xok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{CzOFE{PSd-MUewN\|QyOzV:L3G+
rat neuronal cells	NF\mbXJEgXSxdH;4bYNqfHliYYPzZZk>	NX\VfZh7OTBidV2=	MWmyOEBpenN?	NEThfIREgXSxdH;4bYNqfHliYXfhbY5{fCC{YYSgcoV2em:wYXygZ4VtdHNiYYSgNVAhfU1iYX\0[ZIhOjRiaILz	M4H0XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5Mke2Olc6Lz5zN{K3OlY4QTxxYU6=
P19	NGLje2pEgXSxdH;4bYNqfHliYYPzZZk>		MX[xPEBpenN?	MV7DfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDQNVkh[2WubIOgZYZ1\XJiMUigbJJ{NCCLQ{WwQVAvOc7:TR?=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzR2MkW2OUc,OTd2NEK1OlU9N2F-
MCF7	MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MVLHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IHThfZMh[nliU2LCJIF{e2G7LDDHTVUxRTN3LkdOwG0>	NXzhS2FSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe4OlkxQThpPkG3PFY6ODl6PD;hQi=>
HCT116	MoLwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MWLHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIR3QyOTZiY3XscJMtKEeLNUC9NE4xOjIQvF2=	M1HN[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MkSzO\|A{Lz5zOEK0N\|cxOzxxYU6=
DLD1	MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NXHlSYZvT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hTEyGMTDj[YxteyxiR1m1NF0xNjB\|N988US=>	NE\a[m89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK0N\|cxOyd-MUiyOFM4ODN:L3G+
KPL4	M3fTXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NIOwU\|ZIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBMWEx2IHPlcIx{NCCJSUWwQVAvODV7zszN	NVTa[FZHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyOFM4ODNpPkG4NlQ{PzB\|PD;hQi=>
A549	NIjCSY5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=			Mne1S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gRVU1QSClZXzsd{whT0l3ME2wMlA3PM7:TR?=	NW\kb5lKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyOFM4ODNpPkG4NlQ{PzB\|PD;hQi=>
KPL4	NXvHWJNuTnWwY4Tpc44h[XO\|YYm=		NEHUZ5Q1OCCqcoO=	MYDJcohq[mm2aX;uJI9nKEi\|cEmwJIlvKGi3bXHuJGtRVDRiY3XscJMh[XO\|ZYPz[YQh[XNiZHXwcIV1cW:wIH;mJGVz[kJ{IHzleoVtKGGodHXyJFQxKGi{czygUWVERTBwMUJOwG0>	NWDQRWNRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyOFM4ODNpPkG4NlQ{PzB\|PD;hQi=>
KPL4	M3LaZWZ2dmO2aX;uJIF{e2G7		NETzbmc1OCCqcoO=	NYLKNJlkUW6qaXLpeIlwdiCxZjDId5A6OCCrbjDoeY1idiCNUFy0JINmdGy\|IHHzd4V{e2WmIHHzJIRmeGyndHnvckBw\iCUYX[tNUBt\X[nbDDh[pRmeiB2MDDodpMtKE2HQ{2wMlM{\|ryP	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ2M{ewN{c,OTh{NEO3NFM9N2F-
Jurkat	NVewOWxuTnWwY4Tpc44h[XO\|YYm=	NEDrPFcyKHWP		M2f2dGlvcGmkaYTpc44hd2ZidH:gTHNRQTBiaX6gSmFFTCCmZX\pZ4lmdnRiaIXtZY4hUnW{a3H0JINmdGy\|IHHzd4V{e2WmIHHzJHJKWCCycn;0[YlvKGSnZ4Lh[IF1cW:wIHH0JFEhfU1iYomgW4V{fGW{bjDicI91	NUTKUFBrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0NFg4OTNpPkG4OFA5PzF\|PD;hQi=>
HEK293T	NUm3PY5yTnWwY4Tpc44h[XO\|YYm=			NVK5O\|N5UW6qaXLpeIlwdiCxZjDUUmYu[WyyaHGtbY5lfWOnZDDOSk1s[XCyYVKgZYN1cX[jdHnvckBmgHC{ZYPz[YQhcW5iSFXLNlk{XCClZXzsd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYm=	M3TQXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NEC4O\|E{Lz5zOESwPFcyOzxxYU6=
Jurkat	MmniSpVv[3Srb36gZZN{[Xl?			M1nHb2lvcGmkaYTpc44hd2ZiVF7GMYFteGijLXnu[JVk\WRiTl[tb4FxeGGEIHHjeIl3[XSrb36g[ZhxemW\|c3XkJIlvKE[DRFSg[IVncWOrZX70JIh2dWGwIFr1dotifCClZXzsd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYm=	NYHDRmNnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0NFg4OTNpPkG4OFA5PzF\|PD;hQi=>
SKBR3	MX7GeY5kfGmxbjDhd5NigQ>?		NXzMems5OjRiaILz	M2\hfWlvcGmkaYTpc44hd2ZiSIPwPVAudWWmaXH0[YQhUEWUMjDk[Ydz[WSjdHnvckBqdiCqdX3hckBUU0KUMzDj[YxteyCjZoTldkAzPCCqcoOgZpkhX2W\|dHXyckBjdG:2	MkTwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh6MU[xNVEoRjF6OEG2NVEyRC:jPh?=
SKBR3	MmC3SpVv[3Srb36gZZN{[Xl?		Mnv5NlQhcHK\|	NYX3bXk4UW6qaXLpeIlwdiCxZjDId5A6OC2vZXTpZZRm\CCUYX[g[IVoemGmYYTpc44hcW5iaIXtZY4hW0uEUkOgZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdB?=	NEPuSFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEixOlEyOSd-MUi4NVYyOTF:L3G+
HuH7	MWjBcpRqfmm{YXygZZN{[Xl?		M{PaWFMh\GG7cx?=	M3PCOGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhmeGG2aYTpd{BEKH[rcoXzJIdmdm:2eYDlJFFjKEOxbkGgbY5n\WO2ZXSgbY4hcHWvYX6gTJVJPyClZXzsd{Bie3Onc4Pl[EBieyCJQWDETEBTVkFib4KgNVhUKHKUTlGgcIV3\WxiYX\0[ZIhOyCmYYnzJIJ6KHGUVD3QR3Ih[W6jbInzbZMtKEWFNUC9NE4xODB{Nd88US=>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDl\|NkG5NUc,OTh7M{[xPVE9N2F-
HuH7	NVTrcpFSSW62aY\pdoFtKGG\|c3H5		NVOzOXJVOyCmYYnz	M2XaPGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhmeGG2aYTpd{BEKH[rcoXzJIdmdm:2eYDlJFFjKEOxbkGgbY5n\WO2ZXSgbY4hcHWvYX6gTJVJPyClZXzsd{Bie3Onc4Pl[EBieyCJQWDETEBTVkFib4KgNVhUKHKUTlGgcIV3\WxiYX\0[ZIhOyCmYYnzJJNmdGWldHXkJJdqfGhiNECgcm0hUEOYLUe5OkBidmRiOECwJI5OKGKxY3XwdoV3cXJiYomgdXJVNVCFUjDhcoFtgXOrczygSWM2OD1yLkCwNVLPxE1?	Mo\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh7M{[xPVEoRjF6OUO2NVkyRC:jPh?=
SH-SY5Y	NGi4b\|dP\XW{b4Dyc5Rm[3Srb36gZZN{[Xl?			NYDsXoxJVmW3cn;wdo91\WO2aX;uJIFo[Wmwc4SgZoV1[S2jbYnsc4llKHCncITp[IUhOS12Mj3pcoR2[2WmIITvfIlkcXS7IHnuJIh2dWGwIGPIMXN[PVliY3XscJMh[XO\|ZYPz[YQh[XNibHHjeIF1\SCmZXj5[JJw\2WwYYPlJJJmdGWjc3WsJGVEPTB;MD6wOFI3Qc7:TR?=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTF\|OEi1PUc,OTlzM{i4OVk9N2F-
SH-SY5Y	MnfuUoV2em:ycn;0[YN1cW:wIHHzd4F6	MUOxNEBvVQ>?		NEjyZndP\XW{b4Dyc5Rm[3Srb36gZYdicW6\|dDDi[ZRiNWGveXzvbYQheGWydHnk[UAyNTR{LXnu[JVk\WRidH;4bYNqfHliaX6gdoV1cW6xaXOgZYNq\C2maX\m[ZJmdnSrYYTl[EBpfW2jbjDTTE1UYTW\IHPlcIx{KGG\|c3Xzd4VlKGG\|IHzhZ5RifGViZHXofYRzd2enbnHz[UBz\WynYYPlJIF1KDFyIH7N	MlrzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzM{i4OVkoRjF7MUO4PFU6RC:jPh?=
SKBR3	MYTDfZRwfG:6aXPpeJkh[XO\|YYm=		NV;YWIR5PzJiaILz	NGnNXWpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUU0KUMzDj[YxteyCjZoTldkA4OiCqcoOgZpkh[2WubITpeIVzNWeubzDhd5NigSxiSVO1NF0xNjB2Md88US=>	NX3De\|ltRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0NFU2OjhpPkG5OFA2PTJ6PD;hQi=>
MCF7	M{W1UWN6fG:2b4jpZ4l1gSCjc4PhfS=>			Mne5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BjgSCVUlKgZZN{[XluIFnDOVA:QS54zszN	NFvQZ3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUW2NFM2Oyd-MUm1OlA{PTN:L3G+
SK-BR-3	MXPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			M2nVeGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utRnIuOyClZXzsd{whUUN3ME2wMlAyPTkQvF2=	MnKxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6OU[4OFgoRjF7OEm2PFQ5RC:jPh?=
MCF7	Mn3PRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			MnW5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|LDDJR\|UxRTBwMEG2Ne69VQ>?	NXG0[md6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4PVY5PDhpPkG5PFk3QDR6PD;hQi=>
A431	MUPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MUm3NkBpenN?	MlzGRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNEOxJINmdGy\|IHHmeIVzKDd{IHjyd{whUUN3ME2wMlLPxE1?	NI\WdXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[1OVI{Pyd-MkC2OVUzOzd:L3G+
PP30	MXvGeY5kfGmxbjDhd5NigQ>?	MVqxNFAhfU1?	NFzGVVE{KGi{cx?=	NXroN3pNUW6qaXLpeIlwdiCxZjDoeY1idiCKU2C5NIFteGijIHX4dJJme3OnZDDpckB6\WG\|dDDQVFMxKGOnbHzzJINwNWW6cILld5NqdmdiSGPGMYxi[1picnXwc5J1\XJiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKGinYYSgd4hw[2ticnXzdI9ve2ViYYSgNVAxKHWPIHHmeIVzKDNiaILz	NIfrbXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUGyPVk5Oid-MkGxNlk6QDJ:L3G+
MCF7	MYfGeY5kfGmxbjDhd5NigQ>?	MWWwMlUhfU1?		MV;Jcohq[mm2aX;uJI9nKEi\|cEmwJIlvKGi3bXHuJG1ETjdiY3XscJMh[XO\|ZYPz[YQh[XNiQXv0JIRm\3KjZHH0bY9vKGG2IECuOUB2VSCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJ5M{C2PEc,OjF{N{OwOlg9N2F-
MCF7	MVrGeY5kfGmxbjDhd5NigQ>?	NVLVZ3BCOC53IIXN		MXrJcohq[mm2aX;uJI9nKEi\|cEmwJIlvKGi3bXHuJG1ETjdiY3XscJMh[XO\|ZYPz[YQh[XNiUnHmJIRm\3KjZHH0bY9vKGG2IECuOUB2VSCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	NFXzeJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUK3N\|A3QCd-MkGyO\|MxPjh:L3G+
MCF7	MUHGeY5kfGmxbjDhd5NigQ>?	NGLFXo8xNjVidV2=		MV3Jcohq[mm2aX;uJI9nKEi\|cEmwJIlvKGi3bXHuJG1ETjdiY3XscJMh[XO\|ZYPz[YQh[XNiSIPwPVAh\GWpcnHkZZRqd25iYYSgNE42KHWPIHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	M{GwbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkezNFY5Lz5{MUK3N\|A3QDxxYU6=
MCF7	NH;ZXmpHfW6ldHnvckBie3OjeR?=	M4LRclAvPSC3TR?=		NHHGeGVKdmirYnn0bY9vKG:oIFjzdFkxKGmwIHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgTIVzOiCmZXfyZYRifGmxbjDheEAxNjVidV2gZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJ5M{C2PEc,OjF{N{OwOlg9N2F-
HCT116	MYrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M{TRelQh\GG7cx?=	NU\LUWxHSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMhdWWjc4Xy[YQhd25iZHH5JFQh[nliQ3XscEB1cXSncj3ncI8h[XO\|YYmsJGVEPTB;MD6wN:69VQ>?	M1;qXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEKwNlk4Lz5{MUSyNFI6PzxxYU6=
HCT116	MmL1RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			NWTsb2Q4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[nlibIXtbY5me2OnbnPlJIF{e2G7LDDFR\|UxRTBwMEROwG0>	MorwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF4MEW5O\|UoRjJzNkC1PVc2RC:jPh?=
U87	NYm0cFN2SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			M2HndGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUi3JINmdGy\|IHL5JIx2dWmwZYPj[Y5k\SCjc4PhfUwhTUN3ME2wMlA5Qc7:TR?=	M{K3OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNkC1PVc2Lz5{MU[wOVk4PTxxYU6=
HCT116	NXK3cndVSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			M1:1bWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzMEBKSzVyPUCuNFPPxE1?	MnvqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5MUWxOlUoRjJzN{G1NVY2RC:jPh?=
NCI-H1975	MlTaRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			NHHpfGlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOTl5NTDj[YxteyxiSVO1NF0xNjB\|Nt88US=>	NXv2d49rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3NVUyPjVpPkKxO\|E2OTZ3PD;hQi=>
U87MG	MV3BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			NH\XZ3pCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGW4O21IKGOnbHzzMEBKSzVyPUCuNFg6\|ryP	NYrCZlJjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3NVUyPjVpPkKxO\|E2OTZ3PD;hQi=>
MCF7	NXHMO\|E5TnWwY4Tpc44h[XO\|YYm=	NHn3cYQ2ODBibl2=	MXGyOEBpenN?	NXjiZ\|h[UW6qaXLpeIlwdiCxZjDId5A6OCCrbjDoeY1idiCPQ1[3JINmdGy\|IHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCKZYKyJIRm\3KjZHH0bY9vKGG2IEWwNEBvVSCjZoTldkAzPCCqcoOgZpkhX2W\|dHXyckBjdG:2IH3leIhw\A>?	M1fTSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOE[xOFg4Lz5{MUi2NVQ5PzxxYU6=
MCF7	NWLvXIROTnWwY4Tpc44h[XO\|YYm=	M1LHZ\|UxOCCwTR?=	NW\zTmlXOjRiaILz	NFLsN3NKdmirYnn0bY9vKG:oIFjzdFkxKGmwIHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKFKjZjDk[Ydz[WSjdHnvckBifCB3MECgcm0h[W[2ZYKgNlQhcHK\|IHL5JHdme3Sncn6gZoxwfCCvZYToc4Q>	NFrueXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUi2NVQ5Pyd-MkG4OlE1QDd:L3G+
MCF7	NVPhOFRyTnWwY4Tpc44h[XO\|YYm=	M1ruSlUxOCCwTR?=	MWOyOEBpenN?	NU\rXJp5UW6qaXLpeIlwdiCxZjDId5A6OCCrbjDoeY1idiCPQ1[3JINmdGy\|IHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCDa4Sg[IVoemGmYYTpc44h[XRiNUCwJI5OKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RibXX0bI9l	NVjKToNzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4OlE1QDdpPkKxPFYyPDh5PD;hQi=>
MCF7	NVrCS3VZS3m2b4TvfIlkcXS7IHHzd4F6		NIHJ[YU4OiCqcoO=	M{fySmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[XRiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OD1yLkC1N:69VQ>?	NXvhOHExRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlI4QDZpPkKyNVYzPzh4PD;hQi=>
HepG2	NHH3[5hEgXSxdH;4bYNqfHliYYPzZZk>			NXLQW3NTS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNuIFnDOVA:OC5\|N988US=>	NX;YfWhnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4OFk4PzRpPkKyPFQ6Pzd2PD;hQi=>
SKBR3	Mn7LRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NVW1cohZPzJiaILz	MWfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHXzeJJw\2WwIILlZ4VxfG:{IHTl[olkcWWwdDDoeY1idiCVS1LSN{Bk\WyuczDh[pRmeiB5MjDodpMtKEmFNUC9NE4xODh3zszN	NVjZR2E6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2OFgyQDBpPkKzOlQ5OThyPD;hQi=>
MCF7	NUS2XXNkSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M1PyWVczKGi{cx?=	M1npemFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDlfJBz\XO\|aX7nJIV{fHKxZ3XuJJJm[2WydH;yJIFnfGW{IEeyJIhzeyxiSVO1NF0xNjByOUlOwG0>	M1zCeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkS4NVgxLz5{M{[0PFE5ODxxYU6=
HepG2	NX3UTXhHS3m2b4TvfIlkcXS7IHHzd4F6			M2X2V2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OD1yLkROwG0>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ3NkW1Okc,OjN4NU[1OVY9N2F-
SKBR3	NULYem45TnWwY4Tpc44h[XO\|YYm=	NW[wPYE5OC53IIXN	MV[xPEBpenN?	M3XjRmlvcGmkaYTpc44hd2ZiSGPQPVAhcW5iaIXtZY4hW0uEUkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZYdoemWpYYTpc44hd2ZiaX70doFk\WyudXzhdkBJTVJ{IHH0JFAvPSC3TTDh[pRmeiBzODDodpMh[nliRFHQTUB{fGGrbnnu[{1j[XOnZDDpcY12dm:obIXvdoV{[2WwY3WgcYlkem:\|Y3;wbYMh[W6jbInzbZM>	M3vtVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEW5O\|c4Lz5{M{i1PVc4PzxxYU6=
A549	MYTDfZRwfG:6aXPpeJkh[XO\|YYm=		MnfUNkBl[Xm\|	MWfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEKg[IF6eyCkeTDBcIFu[XKEbIXlJIF{e2G7LDDJR\|UxRTBwMUZOwG0>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl2N{e5OEc,OjN7NEe3PVQ9N2F-
CL1-5	MXHGeY5kfGmxbjDhd5NigQ>?	NF\rTlMzKHWP	MUSxOkBpenN?	Mo\6TY5pcWKrdHnvckBw\iCKU2C5NEBqdiCqdX3hckBEVDFvNTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YhfG:2YXygRYt1KGG2IEKgeW0h[W[2ZYKgNVYhcHK\|IHL5JHdme3Sncn6gZoxwfHSrbnegZY5idHm\|aYO=	NWn6Z4V5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0Nlg4PzdpPkK0OFI5Pzd5PD;hQi=>
L6	MWDDfZRwfG:6aXPpeJkh[XO\|YYm=		NFfjfZQ4OiCqcoO=	MojHR5l1d3SxeHnjbZR6KGGpYXnud5QhemG2IFy2JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCDbHHtZZIhSmy3ZTDhd5NigSxiSVO1NF03\|ryP	NFLrdHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW4NFU{OSd-MkS1PFA2OzF:L3G+
Sf9	M1O5eWZ2dmO2aX;uJIF{e2G7		M331UlE3KGi{cx?=	MUXEbZNxdGGlZX3lcpQhd2ZiR12tRm9FUVC\IH\yc40hcHWvYX6g[pVtdCCuZX7neIghUFOSOUCgZYxxcGFiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{NWmwZnXjeIVlKFOoOTDj[YxteyCjZoTldkAyPiCqcoOgZpkh\my3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeTygTWM2OD1yLkC3OO69VQ>?	NVrWUmlNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OVE1PDFpPkK0O\|UyPDRzPD;hQi=>
MDA-kb2	NWO5OIh{TnWwY4Tpc44h[XO\|YYm=		NVLhbZpNOThiaILz	NV;MO2VXUW6qaXLpeIlwdiCxZjDIV3A6OCCrbjDoeY1idiCPRFGtb4IzKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDncJVkd2OxcoTpZ49q\CC{ZXPldJRwei2mZYDlcoRmdnRibIXjbYZmemG\|ZTDlfJBz\XO\|aX;uJIFnfGW{IEG4JIhzeyCkeTDmbZJm\my7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhUUN3MEywMlAy\|ryP	MnHHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OES5N\|YoRjJ2OUi0PVM3RC:jPh?=
MCF7	NFK2W\|NCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NIjVXXE4OiCqcoO=	MoTmRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHMwWE2VIHHzd4F6NCCLQ{WwQVAvODUQvF2=	NV\YOGZHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwO\|U4PjJpPkK1NFc2PzZ{PD;hQi=>
MDA-MB-231	Mlq3R5l1d3SxeHnjbZR6KGG\|c3H5		MmXvO\|IhcHK\|	NF7UR2lEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;MD6wOe69VQ>?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFyNUmyOEc,OjVzMEW5NlQ9N2F-
LNCAP	MmX3R5l1d3SxeHnjbZR6KGG\|c3H5		MXi3NkBpenN?	NITNR4tEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNVkODUDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvPDQQvF2=	Ml;wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMEW5NlQoRjJ3MUC1PVI1RC:jPh?=
MDA-MB 231	MkXaSpVv[3Srb36gZZN{[Xl?	MWqwMlUh[W6mIEWgeW0>		NI[5cY9KdmirYnn0bY9vKG:oIFjTVFkxKGmwIHj1cYFvKE2GQT3NRkAzOzFiY3XscJMh[XO\|ZYPz[YQhcW6lcnXhd4UhcW5iSGPQO\|AheHKxdHXpckBt\X[nbIOgZZQhOC53IHHu[EA2KHWPIHL5JHdme3Sncn6gZoxwfCCvZYToc4Q>	NVfwRW9rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNFU6OjRpPkK1NVA2QTJ2PD;hQi=>
HUVEC	M4jVXmN6fG:2b4jpZ4l1gSCjc4PhfS=>		M{HQdFczKGi{cx?=	MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBJXV[HQzDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODF7zszN	NG\CXmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O\|A3Pyd-MkWyO\|cxPjd:L3G+
A431	NILZTmNEgXSxdH;4bYNqfHliYYPzZZk>		MmqxO\|IhcHK\|	NFrSSmpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPDNzIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xPM7:TR?=	NIW5S5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O\|A3Pyd-MkWyO\|cxPjd:L3G+
BGC823	NXLDdpo6S3m2b4TvfIlkcXS7IHHzd4F6		MojpO\|IhcHK\|	M2fiRWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJISzh{MzDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODUQvF2=	NH;uZVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O\|A3Pyd-MkWyO\|cxPjd:L3G+
HepG2	M3riV2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NVzMXmtwPzJiaILz	NIO5bXZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODUQvF2=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{C2O{c,OjV{N{ewOlc9N2F-
MDA-MB-231	MnToR5l1d3SxeHnjbZR6KGG\|c3H5		MX:3NkBpenN?	M2LnNGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkC1{txO	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{C2O{c,OjV{N{ewOlc9N2F-
A549	NV7jfmdxS3m2b4TvfIlkcXS7IHHzd4F6		M1vrT\|czKGi{cx?=	NVzRVWkzS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODl5zszN	NX[3[VBMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|cxPjdpPkK1Nlc4ODZ5PD;hQi=>
HL7702	NXK0NHJyS3m2b4TvfIlkcXS7IHHzd4F6		M3HMTlczKGi{cx?=	NUfpNWp2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEx5N{CyJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5zNEJOwG0>	NFvQOW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O\|A3Pyd-MkWyO\|cxPjd:L3G+
SW480	MmPGR5l1d3SxeHnjbZR6KGG\|c3H5		MnfYO\|IhcHK\|	NHLSU4VEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUXzR6MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvOzIQvF2=	M2HFOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3NFY4Lz5{NUK3O\|A3PzxxYU6=
HeLa	NWraOFNPS3m2b4TvfIlkcXS7IHHzd4F6		MmjmO\|IhcHK\|	MmCyR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyPUCuO\|k5\|ryP	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{C2O{c,OjV{N{ewOlc9N2F-
MDA-MB 231	M3vwPWZ2dmO2aX;uJIF{e2G7	M1LXb\|AvPSC3TR?=	MVOyOEBpenN?	NHXmeXRKdmirYnn0bY9vKEi\|cEmwJIlvKGi3bXHuJG1FSS2PQjCyN\|Eh[2WubIOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iSGPQO\|AheHKxdHXpckBt\X[nbDDheEAxNjVidV2gbY5kfWKjdHXkJIZweiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JI1mfGixZB?=	Mo\3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{ewOlcoRjJ3Mke3NFY4RC:jPh?=
MCF7	NULMU\|B1S3m2b4TvfIlkcXS7IHHzd4F6		MnPjO\|IhcHK\|	NXvRRYN5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliTWTTM3BOWyCjc4PhfUwhUUN3ME2wMlA1OjgQvF2=	NX;Bc\|JERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OVYzQTlpPkK1O\|U3Ojl7PD;hQi=>
MCF7	NF;MSIxHfW6ldHnvckBie3OjeR?=		M4[4dFI1KGi{cx?=	Mn\UTY5pcWKrdHnvckBw\iCKU2C5NEBqdiCqdX3hckBOS0Z5IHPlcIx{KGG\|c3Xzd4VlKGG\|IIDBb5Qh\GWpcnHkZZRqd25iYYSgOUB1cW2nczDJR\|UxKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	NHzNVlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe1OlI6QSd-MkW3OVYzQTl:L3G+
MCF7	M3fye2Z2dmO2aX;uJIF{e2G7		NV3PT2RzOjRiaILz	MmTWTY5pcWKrdHnvckBw\iCKU2C5NEBqdiCqdX3hckBOS0Z5IHPlcIx{KGG\|c3Xzd4VlKGG\|IFjldlIh\GWpcnHkZZRqd25iYYSgOUB1cW2nczDJR\|UxKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	M2TzOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{W2Nlk6Lz5{NUe1OlI6QTxxYU6=
MCF7	M334fGZ2dmO2aX;uJIF{e2G7		MUCyOEBpenN?	NGn4cIlKdmirYnn0bY9vKG:oIFjTVFkxKGmwIHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgR4RsPiCmZXfyZYRifGmxbjDheEA2KHSrbXXzJGlEPTBiYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	NXHtWZlDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OVYzQTlpPkK1O\|U3Ojl7PD;hQi=>
MCF7	MU\GeY5kfGmxbjDhd5NigQ>?		MUKyOEBpenN?	NVrvXGNrUW6qaXLpeIlwdiCxZjDIV3A6OCCrbjDoeY1idiCPQ1[3JINmdGy\|IHHzd4V{e2WmIHHzJHJi\iCmZXfyZYRifGmxbjDheEA2KHSrbXXzJGlEPTBiYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	M3rqdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{W2Nlk6Lz5{NUe1OlI6QTxxYU6=
MCF7	MnLaSpVv[3Srb36gZZN{[Xl?		NWPSellWOjRiaILz	MYPDbIFv\2ViaX6gR4RkOzdiZYjwdoV{e2mxbjDpckBpfW2jbjDNR2Y4KGOnbHzzJIF1KDVidHnt[ZMhUUN3MDDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	NXLEbJpuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OVYzQTlpPkK1O\|U3Ojl7PD;hQi=>
MCF7	M4jCUmZ2dmO2aX;uJIF{e2G7		NGHLXYkzPCCqcoO=	M1XBdWNp[W6pZTDpckBxOjNiZYjwdoV{e2mxbjDpckBpfW2jbjDNR2Y4KGOnbHzzJIF1KDVidHnt[ZMhUUN3MDDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	Mkf0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NU[yPVkoRjJ3N{W2Nlk6RC:jPh?=
MCF7	MVXGeY5kfGmxbjDhd5NigQ>?		M1flZ\|I1KGi{cx?=	NXzhbGhwUW6qaXLpeIlwdiCxZjDIV3A6OCCrbjDoeY1idiCPQ1[3JINmdGy\|IHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCqZXH0JJNpd2OtIILld5BwdnOnLX3l[IlifGWmIFjTVFkxKHC{b3T1Z5Rqd25iYYSgOUB1cW2nczDJR\|UxKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXNicnXsZZRqfmVidH:geoVpcWOuZT30doVifGWmIHPvcpRzd2x?	Ml\YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NU[yPVkoRjJ3N{W2Nlk6RC:jPh?=
MCF7	M2nrOWZ2dmO2aX;uJIF{e2G7		NGDIXWwzPCCqcoO=	NFz1TmJKdmirYnn0bY9vKG:oIFjTVFkxKGmwIHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKGinYYSgd4hw[2ticnXzdI9ve2VvbXXkbYF1\WRiSGPQO\|AheHKxZIXjeIlwdiCjdDC1JJRqdWW\|IFnDOVAh[W[2ZYKgNlQhcHK\|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqeyC{ZXzheIl3\SC2bzD2[Yhq[2ynLYTy[YF1\WRiY3;ueJJwdA>?	M4TVSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{W2Nlk6Lz5{NUe1OlI6QTxxYU6=
MCF7	NVGwblJCTnWwY4Tpc44h[XO\|YYm=		MW[yOEBpenN?	MWPJcohq[mm2aX;uJI9nKEiVUEmwJIlvKGi3bXHuJG1ETjdiY3XscJMh[XO\|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJIhm[XRic3jvZ4shemW\|cH;ud4UudWWmaXH0[YQhUFOSMkegdJJw\HWldHnvckBifCB3IITpcYV{KEmFNUCgZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpd{Bz\WyjdHn2[UB1dyC4ZXjpZ4xmNXS{ZXH0[YQh[2:wdILvcC=>	NWHDWXI{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OVYzQTlpPkK1O\|U3Ojl7PD;hQi=>
PC12	NFLoVG9HfW6ldHnvckBie3OjeR?=	NXyyUZRCOTBidV2=	MkPTN{B1dyBzNjDodpM>	NGLDRYZKdmirYnn0bY9vKG:oIFStZZNx[XK2YYTlJIJqd3O7boTo[ZNqeyCrbjDyZZQhWENzMjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YhcW62cnHj[YxtfWyjcjDEMYF{eGG{dHH0[UBkd262ZX70JIF1KDFyIIXNJI1m[XO3cnXkJIF1KDNidH:gNVYhcHK\|IHL5JG8ueGi2aHHsZYxl\Wi7ZHWvUk1i[2W2eXytUE1kgXO2ZXnu[UBl\XKrdnH0bZpifGmxbjD0[YNpdmmzdXWtZoF{\WRiSGDMR{BidmGueYPpd{Bz\WyjdHn2[UB1dyC4ZXjpZ4xmNXR?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ2Mke2PUc,OjZ4NEK3Olk9N2F-
PC12	NGLuPZZHfW6ldHnvckBie3OjeR?=	NX3hd5o{OTBidV2=	NVfVelhZPiC2bzCxOkBpenN?	NGX1boFKdmirYnn0bY9vKG:oIFStZZNx[XK2YYTlJIJqd3O7boTo[ZNqeyCrbjDyZZQhWENzMjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YhfG:2YXygSE1ie3CjcoTheIUh[2:wdHXueEBifCBzMDD1UUBu\WG\|dYLl[EBifCB4IITvJFE3KGi{czDifUBQNXCqdHjhcIFt\GWqeXTlM24u[WOndInsMWwu[3m\|dHXpcoUh\GW{aY\heIl7[XSrb36geIVkcG6rcYXlMYJie2WmIFjQUGMh[W6jbInzbZMhemWuYYTpeoUhfG9idnXobYNt\S22cnXheIVlKGN?	NGLmPYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[0Nlc3QSd-Mk[2OFI4Pjl:L3G+
PC12	NEfO[ohHfW6ldHnvckBie3OjeR?=		Ml7RNlQhcHK\|	M{HpXWlvcGmkaYTpc44hd2ZiRD3hd5BienSjdHWgZolwe3mwdHjld4l{KGmwIILheEBRSzF{IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDv[kBqdnS{YXPlcIx2dGG{IFStZZNx[XK2YYTlJIxmfmWuIIXwJJRwKDFyIIXNJIFnfGW{IEK0JIhzeyCkeTDPMZBpfGijbHHs[IVpgWSnL16tZYNmfHmuLVytZ5l{fGWrbnWg[IVzcX[jdHn6ZZRqd25idHXjbI5qeXWnLXLhd4VlKEiSTFOgZY5idHm\|aYO=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ2Mke2PUc,OjZ4NEK3Olk9N2F-
PC12	M4fGOmZ2dmO2aX;uJIF{e2G7	MXX1dEB1dyBzMDD1US=>	NYnFNWl7OjRiaILz	M1LqOGlvcGmkaYTpc44hd2ZiRD3hd5BienSjdHWgZolwe3mwdHjld4l{KGmwIILheEBRSzF{IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDv[kBFNWG\|cHHyeIF1\SCuZY\lcEBqdiClZXzsJIN2dHS3cnWgcYVlcXWvIIXwJJRwKDFyIIXNJIFnfGW{IEK0JIhzeyCkeTDPMZBpfGijbHHs[IVpgWSnL16tZYNmfHmuLVytZ5l{fGWrbnWg[IVzcX[jdHn6ZZRqd25idHXjbI5qeXWnLXLhd4VlKEiSTFOgZY5idHm\|aYO=	NInjNmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[0Nlc3QSd-Mk[2OFI4Pjl:L3G+
A549	M2CycGZ2dmO2aX;uJIF{e2G7		MlqxNVIhfG9iMkSgbJJ{	NUHscYhYUW6qaXLpeIlwdiCxZjDId5A6OCCrbjDoeY1idiCDNUS5JINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKEWJRmKgcIV3\Wy\|IHH0JIZqfmVidHnt[ZMhUUN3MDD2ZYx2\SCjZoTldkAyOiC2bzCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	M2\hdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{S1PFU1Lz5{Nke0OVg2PDxxYU6=
A549	NWfiXGwxTnWwY4Tpc44h[XO\|YYm=		NV;wfpF[OTJidH:gNlQhcHK\|	MWTJcohq[mm2aX;uJI9nKEi\|cEmwJIlvKGi3bXHuJGE2PDliY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gTIVzOiCuZY\lcJMh[XRiZnn2[UB1cW2nczDJR\|UxKH[jbIXlJIFnfGW{IEGyJJRwKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	Mn:wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5NEW4OVQoRjJ4N{S1PFU1RC:jPh?=
A549	M4\vdGZ2dmO2aX;uJIF{e2G7		NXfQSHZzOTJidH:gNlQhcHK\|	NVzaXW1kUW6qaXLpeIlwdiCxZjDId5A6OCCrbjDoeY1idiCDNUS5JINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKENvUnHmJIxmfmWuczDheEBncX[nIITpcYV{KEmFNUCgeoFtfWViYX\0[ZIhOTJidH:gNlQhcHK\|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	NYTiS4M{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OFU5PTRpPkK2O\|Q2QDV2PD;hQi=>
SKBR3	MkDSSpVv[3Srb36gZZN{[Xl?			MlLDTY5pcWKrdHnvckBw\iCKc4C5NEBqdiCqdX3hckBUU0KUMzDj[YxteyxiSVO1NF0xNjB5zszN	M{DLc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OES0Olg6Lz5{Nki0OFY5QTxxYU6=
BA/F3	NGjoWJhHfW6ldHnvckBie3OjeR?=		Ml3xOFghcHK\|	MVTJcohq[mm2aX;uJI9nKGmvYYTpcoljNXKnc3nzeIFvfCCEQ2KtRWJNKFR\|MUXJJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W\|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhfHK7cHHuJIJtfWViZYjjcJV{cW:wIHHzd4F6NCCLQ{WwQVHPxE1?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjh2NE[4PUc,OjZ6NES2PFk9N2F-
BA/F3	NXH4SnFQTnWwY4Tpc44h[XO\|YYm=		MkmwOFghcHK\|	MljrTY5pcWKrdHnvckBw\iCrbXH0bY5q[i2{ZYPpd5RidnRiQlPSMWFDVCCHMkW1T{BufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgRmEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIJ6KHS{eYDhckBjdHWnIHX4Z4x2e2mxbjDhd5NigSxiSVO1NF0y\|ryP	Ml:wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ6NES2PFkoRjJ4OES0Olg6RC:jPh?=
BA/F3	NI\TR3JHfW6ldHnvckBie3OjeR?=		M13BSVQ5KGi{cx?=	MWHJcohq[mm2aX;uJI9nKEKFUj3BRmwhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSkFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KGK7IITyfZBidiCkbIXlJIV5[2y3c3nvckBie3OjeTygTWM2OD13zszN	NWLGfHdnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4OFQ3QDlpPkK2PFQ1Pjh7PD;hQi=>
MDA-MB-231	MYfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M{naVFczKGi{cx?=	NIHWcmxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WUz;QUXMh[XO\|YYmsJGFkfGm4aYT5QVAvODcQvF2=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzByM{WxOkc,OjdyMEO1NVY9N2F-
MDA-MB-231	M1HsfWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NFXGbXM4OiCqcoO=	M4e0SmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvODQQvF2=	NUC0dI1pRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkeyOlY6QTdpPkK3NlY3QTl5PD;hQi=>
HeLa	NEXKSVhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M4Hob\|czKGi{cx?=	NWrHXHRySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTB;MD6wOu69VQ>?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzJ4Nkm5O{c,Ojd{Nk[5PVc9N2F-
SNU638	NFfTboZCdnSrY3HuZ4VzKGG\|c3H5		MYe3NkBpenN?	M2jMT2FvfGmlYX7j[ZIh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTUnU3OzhiY3XscJMhdWWjc4Xy[YQh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlA{\|ryP	M3rkOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MkizO\|g5Lz5{N{K4N\|c5QDxxYU6=
Caki1	MXvBcpRq[2GwY3XyJIF{e2G7		M3POOVczKGi{cx?=	MVXBcpRq[2GwY3XyJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ3HrbVEh[2WubIOgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OD1yLkC1Ou69VQ>?	NVPD[Y5KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkeyPFM4QDhpPkK3Nlg{Pzh6PD;hQi=>
A549	MWHBcpRq[2GwY3XyJIF{e2G7		MlPMO\|IhcHK\|	M17TSGFvfGmlYX7j[ZIh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJI1m[XO3cnXkJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTB;MD6xNFnPxE1?	NHrnSG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{K4N\|c5QCd-MkeyPFM4QDh:L3G+
MDA-MB-231	MnPsRY51cWOjbnPldkBie3OjeR?=		MoLuO\|IhcHK\|	Mo\pRY51cWOjbnPldkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NF0xNjFzzszN	NUXX[4FiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkeyPFM4QDhpPkK3Nlg{Pzh6PD;hQi=>
HCT116	NWTyR\|FUSW62aXPhcoNmeiCjc4PhfS=>		NXPabIxwPzJiaILz	NFvi[3dCdnSrY3HuZ4VzKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KG2nYYP1doVlKGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE4yPc7:TR?=	NYT2ZWd6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkeyPFM4QDhpPkK3Nlg{Pzh6PD;hQi=>
SKBR3	NX[ydFNFSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NEK2U\|YyKHSxIEOg[IF6ew>?	NIPZW3pCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGhmejJvb4\ldoV5eHKnc4PpcochcHWvYX6gV2tDWjNiY3XscJMh[W[2ZYKgNUB1dyB\|IHThfZMh[nliTWTTJIF{e2G7LDDHTVUxRTBwNEROwG0>	NHzCO249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e4N\|k4Pyd-Mke3PFM6Pzd:L3G+
NCI-H1975	MWjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M2r1bVEhfG9iMzDkZZl{	NFThRppCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIdm\mm2aX7pZk1z\XOrc4ThcpQhcHWvYX6gUmNKNUhzOUe1JINmdGy\|IHHmeIVzKDFidH:gN{Bl[Xm\|IHL5JG1VWyCjc4PhfUwhT0l3ME2wMlU3\|ryP	MlPGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5OEO5O\|coRjJ5N{izPVc4RC:jPh?=
RPMI8226	M2LENmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NEHIRWs4OiCqcoO=	MXrHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDSVG1KQDJ{NjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSVL2DNV{Bie3OjeTygS2k2OD1yLkCwN:69VQ>?	Mnj3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlyNUewOFMoRjJ7MEW3NFQ{RC:jPh?=
MDA-MB-231	MnXGRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M3nwTFczKGi{cx?=	MXvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlA3\|ryP	MoLkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzN{KwPFUoRjJ7MUeyNFg2RC:jPh?=
A549	M2PDWGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MkTRO\|IhcHK\|	MmS5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNUS5JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFnDOVA:OC5zzszN	NGTicWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG3NlA5PSd-MkmxO\|IxQDV:L3G+
NCI-H1975	NX;FbFExSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M37hVFczKGi{cx?=	MU\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3INVk4PSClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdCCWaYTldkA6PiCDcYXlc5V{KE:wZTDTc4x2fGmxbjDj[YxtKHC{b3zp[oVz[XSrb36gZZN{[XluIFfJOVA:OC53Nt88US=>	M3PRZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MkCyOFAzLz5{OUKwNlQxOjxxYU6=
A549	M2XWemZ2dmO2aX;uJIF{e2G7	MUO1JJRwKDFyIIXN	NFPr[HAzPCCqcoO=	Ml7FTY5pcWKrdHnvckBw\iCKU2C5NIFteGijIHnuJIh2dWGwIFG1OFkh[2WubIOgZZN{\XO\|ZXSgZZMhfXC{ZXf1cIF1cW:wIH;mJGhUWDlyYXzwbIEh\XiycnXzd4lwdiCjdDC1JJRwKDFyIIXNJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	MlLxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2OE[5OVQoRjJ7NEi2PVU1RC:jPh?=
A549	NX\EcHg2TnWwY4Tpc44h[XO\|YYm=	MUi1JJRwKDFyIIXN	NF3ic\|UzPCCqcoO=	MkXITY5pcWKrdHnvckBw\iCKU2C5NIJmfGFiaX6gbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{B2eHKnZ4XsZZRqd25ib3[gTHNRQTCkZYThJIV5eHKnc4Ppc44h[XRiNTD0c{AyOCC3TTDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	NFTOelM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS4Olk2PCd-Mkm0PFY6PTR:L3G+
SKBR3	M3G3bGZ2dmO2aX;uJIF{e2G7		M{[4XFI1KGi{cx?=	NXS4RYdzUW6qaXLpeIlwdiCxZjDIV3A6OCCjdDDOMZRmem2rboXzJIlvKGi3bXHuJHNMSlJ\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBT[WZzIIDyc5RmcW5iZHXndoFl[XSrb36gbY5kfWKjdHXkJIZweiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	MnjVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF3OUGwNVYoRjNzNUmxNFE3RC:jPh?=
SKBR3	NFewTW5HfW6ldHnvckBie3OjeR?=		MnLWNlQhcHK\|	MV;Jcohq[mm2aX;uJI9nKEiVUEmwJIF1KE5vdHXycYlvfXNiaX6gbJVu[W5iU1vCVlMh[2WubIOgZZN{\XO\|ZXSgZZMhcW6mdXP0bY9vKG:oIFPET\|QheHKxdHXpckBl\We{YXTheIlwdiCrbnP1ZoF1\WRiZn;yJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTV7MUCxOkc,OzF3OUGwNVY9N2F-
SKBR3	MkLXSpVv[3Srb36gZZN{[Xl?		M3f0XFI1KGi{cx?=	MV3Jcohq[mm2aX;uJI9nKEiVUEmwJIF1KE5vdHXycYlvfXNiaX6gbJVu[W5iU1vCVlMh[2WubIOgZZN{\XO\|ZXSgZZMhcW6mdXP0bY9vKG:oIFjldlIheHKxdHXpckBl\We{YXTheIlwdiCrbnP1ZoF1\WRiZn;yJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTV7MUCxOkc,OzF3OUGwNVY9N2F-
SKBR3	Ml;CSpVv[3Srb36gZZN{[Xl?		M3T4WlI1KGi{cx?=	NETvVJFKdmirYnn0bY9vKG:oIFjTVFkxKGG2IF6teIVzdWmwdYOgbY4hcHWvYX6gV2tDWjNiY3XscJMh[XO\|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJGFMXCCycn;0[YlvKGSnZ4Lh[IF1cW:wIHnuZ5Vj[XSnZDDmc5IhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	NU\CWo5PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{G1PVExOTZpPkOxOVkyODF4PD;hQi=>

... Click to View More Cell Line Experimental Data

In vivo

Geldanamycin (50 mg//kg) shows 30% inhibition on pl85-associated phosphotyrosine levels in FRE/erbB-2 mice. ^[6]

Protocol

Kinase Assay: ^[1]	- Collapse Isothermal Titration Calorimetry (ITC) of Nucelotide Binding: The titration experiments are performed using the MSC system. In each experiment, 16 aliquots of 15 μL of geldanamycin (300 μM in 1% DMSO) are injected into 1.3 mL of protein (31 μM in 20 mMTris-HCl, pH 7.5, 1 mMEDTA) at 25 °C, and the resulting data are fit after subtracting the heats of dilution. Heats of dilution are determined in separate experiments from addition of geldanamycin into buffer and buffer into protein. No evidence for binding of DMSO in the nucleotide binding site is observed. Titration data are fit using a nonlinear least-squares curve-fitting algorithm with three floating variables: stoichiometry, binding constant (K_b) 1/K_d), and change of enthalpy of interaction (ΔH°). Dissociation constants estimated for geldanamycin binding to intact yeast Hsp90 is 1.22 μM, and for binding to Hsp90 N-terminal domain is 0.78 μM. No meaningful heat is observed with binding to the C-terminal fragment.
Cell Research: ^[2]	- Collapse Cell lines: A2780 human ovarian cell line Concentrations: 0.001-10 μM Incubation Time: 3 hours Method: Exponentially growing cells are treated with Geldanamycin and at various times DNA synthesis is assessed by incorporation of bromodeoxyuridine (BrdUrd) and flow cytometric analysis. No marked difference in total cell number is noted during this time course for treated and untreated cultures. BrdUrd (10 μM) is incorporated over a 4-h incubation period at 37 °C and cells are harvested and fixed in 70% ethanol. After denaturation of the DNA with 2 N HC1, cells are incubated with an anti-BrdUrd mouse monoclonal antibody followed by a fluorescein isothiocyanate (FITC)-linked goat anti-mouse IgG. Cells are stained for 30 minutes at room temperature with propidium iodide and analysed by flow cytometry using a Coulter EPICS Profile Analyzer. (Only for Reference)
Animal Research: ^[6]	- Collapse Animal Models: FRE/erbB-2 tumors in nu/nu mice Dosages: 50 mg/kg Administration: Administered via i.p. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	36 mg/mL warmed (64.21 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Geldanamycin (NSC 122750) SDF

Molecular Weight	560.64
Formula	C₂₉H₄₀N₂O₉
CAS No.	30562-34-6
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C(=C(C1)C2=O)OC)C)OC)OC(=O)N)C)C)O)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00003969	Completed	Drug: tanespimycin	Unspecified Adult Solid Tumor Protocol Specific	Cancer Research UK\|National Cancer Institute (NCI)	August 1998	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Antineoplastic and Immunosuppressive Antibiotics Inhibitors with Unique Features

Selective HSP90 Inhibitor

NVP-BEP800 : HSP90β-selective, IC50=58 nM.
Most Potent HSP90 Inhibitor

KW-2478 : HSP90, IC50=3.8 nM.
HSP90 Inhibitor in Clinical Trial

17-AAG (Tanespimycin) : Phase III for Gastrointestinal Stromal Tumors.
Newest HSP90 Inhibitor

XL888 : ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

Choose Your Country or Region

By Signaling Pathways

By product type

Geldanamycin (NSC 122750)